Arrowhead Pharmaceuticals ARWR Estimates

NASDAQ ARWR
$84.88 -1.61 (-1.86%)
As of: Sep 4, 2026 · 11:47 AM EDT
Analyst Estimates

Arrowhead Pharmaceuticals, Inc. Revenue Estimates

Periods 25
Next Period Q4 26
Consensus 70.64 M

Analysts expect Arrowhead Pharmaceuticals, Inc. to report revenue of 70.64 M for Q4 26, against a range of 63.75 M to 77.52 M. The most recent reported quarter, Q3 26, came in at 75.25 M, a 66.6% beat against the 45.18 M consensus.

Metric Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 0.002.50 M542.71 M27.77 M256.47 M264.03 M73.74 M75.25 M--------
High Estimate 60.00 M74.02 M128.11 M48.46 M176.87 M216.27 M81.97 M48.65 M77.52 M44.35 M32.85 M34.34 M94.55 M196.10 M157.75 M101.12 M
Low Estimate 52.85 M67.55 M113.81 M40.93 M151.23 M187.50 M72.12 M41.70 M63.75 M37.38 M27.32 M29.70 M87.60 M165.92 M137.30 M93.14 M
Consensus Estimate 56.43 M70.78 M120.96 M44.69 M164.05 M201.88 M77.05 M45.18 M70.64 M40.87 M30.09 M32.02 M91.08 M181.01 M147.52 M97.13 M
Analyst Estimates

Arrowhead Pharmaceuticals, Inc. Earnings Per Share (EPS) Estimates

Periods 25
Next Period Q4 26
Consensus -1.20

Analysts expect Arrowhead Pharmaceuticals, Inc. to report earnings per share of -1.20 for Q4 26, against a range of -1.30 to -1.10. The most recent reported quarter, Q3 26, came in at -1.36, a 10.6% miss against the -1.23 consensus.

Metric Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -1.36-1.392.75-1.26-0.110.22-0.93-1.36--------
High Estimate -1.07-0.44-0.18-0.92-0.100.04-1.00-1.14-1.10-1.29-1.26-1.41-1.03-0.47-0.55-1.22
Low Estimate -1.25-0.54-0.20-1.10-0.120.04-1.14-1.32-1.30-1.55-1.50-1.69-1.09-0.51-0.65-1.40
Consensus Estimate -1.16-0.49-0.19-1.01-0.110.04-1.07-1.23-1.20-1.42-1.38-1.55-1.06-0.49-0.60-1.31